Quest Diagnostics Incorporated
DGX
Positions held
Your positionsDGX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Quest Diagnostics is well-positioned in the diagnostics industry, benefiting from a growing demand for healthcare services and testing, especially in a post-pandemic environment.
- In Q2 2026, Quest Diagnostics reported a revenue increase of 5% compared to the previous quarter, reaching $3.0 billion.
- The company's gross margin improved to 33.7% in Q2 2026, up from 32.5% in the prior quarter.
- Despite its strengths, Quest Diagnostics faces challenges such as high debt levels and competitive pressures in the healthcare sector.
- The operating margin was 15.1% in Q2 2026, indicating only a slight improvement from 13.9% in Q1 2026, suggesting limited operational efficiency gains.
- The stock has a beta of 0.54, indicating lower volatility compared to the market, but the overall market sentiment remains neutral with a score of 12.00.
Fundamentals
| Market cap | $25.48B | Enterprise value | $31.64B | Trailing P/E | 24.50 | Forward P/E | 19.18 |
| PEG | 1.48 | Price / book | 3.38 | Beta | 0.54 | Dividend yield | 1.49% |
| Revenue growth | 10.2% | Earnings growth | 15.0% | Gross margin | 33.2% | Operating margin | 15.2% |
| Profit margin | 9.2% | ROE | 14.6% | ROA | 6.4% | Debt / equity | 0.81 |
| Current ratio | 1.59 | Free cash flow | $909.63M | Analyst recommendation | buy | Mean target | $248.80 |
| 52w high | $248.84 | 52w low | $171.18 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $3.0B | $2.9B | $2.8B | $2.8B | $2.8B | — |
| Op margin | 15.1% | 14.0% | 13.8% | 13.7% | 15.9% | — |
| Net income | $320M | $252M | $245M | $245M | $282M | — |
| Gross margin | 33.7% | 32.5% | 32.4% | 33.7% | 34.2% | — |
| Gross profit | $1.0B | $942M | $910M | $949M | $943M | — |
| Operating income | $459M | $404M | $386M | $386M | $438M | — |
- Revenue +5% vs prior quarter ($3.0B vs $2.9B).
- Gross margin 33.7% (was 32.5% prior quarter).
- Operating margin expanded to 15.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $11.0B | $9.9B | $9.3B | $9.9B | — |
| Op margin | 14.1% | 13.6% | 13.6% | 14.4% | — |
| Net income | $992M | $871M | $854M | $946M | — |
| Gross margin | 33.2% | 32.9% | 33.0% | 34.7% | — |
| Gross profit | $3.7B | $3.2B | $3.1B | $3.4B | — |
| Operating income | $1.6B | $1.3B | $1.3B | $1.4B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Is Hims & Hers Stock Ready For A Longer Cash Burn?
2026-10-08 · Oracle Insider Buys $3.5 Million in Stock Amid OpenAI Swings
2026-10-08 · Leerink Partners Adjusts Quest Diagnostics Price Target to $265 From $254
2026-10-06 · Barclays Adjusts Price Target on Quest Diagnostics to $260 From $250, Keeps Overweight Rating
2026-10-06 · Evercore ISI Adjusts Price Target on Quest Diagnostics to $235 From $240, Keeps In Line Rating
2026-10-06 · Quest Diagnostics Inc's Dividend Analysis
2026-10-05 · Quest Diagnostics’ Quarterly Earnings Preview: What You Need to Know
2026-10-05 · Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus
2026-10-01 · Apple Is Betting Improved Heart and Health Insights Will Boost Watch Sales
2026-09-25 · Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?
Price (daily)
Full chart · RSI · MACD · patterns